BeOne Medicines (ONC) Rebranded And Lifted Guidance, Is It Still Cheap?

BeOne Medicines (ONC) has been drawing investor attention after a recent rebranding from BeiGene and a move to an AG structure, shifting focus toward its oncology portfolio and global partnerships.

Recent trading paints a mixed picture for BeOne Medicines. The share price is around US$350.84 after a small 1-day decline of 0.74%, with a 90-day share price return of 29.87% and a 1-year total shareholder return of 4.92%. However, the 3-year total shareholder return of 84.09% contrasts with a 5-year total shareholder return that is down 7.56%, hinting that momentum has picked up more recently than over the full five year stretch.

Spot 16 high quality undiscovered gems that, like BeOne Medicines, combine active cancer pipelines with meaningful revenue and earnings growth already showing up in the numbers.

BeOne Medicines now trades near US$350 with stronger recent returns than its five year record and a fresh AG structure in place. Does that balance of momentum and restructuring still leave enough upside to justify the risk?

Most Popular Narrative: 19% Undervalued

Against the last close of $350.84, the most followed narrative pegs BeOne Medicines at a fair value of about $433, which implies meaningful upside once you factor in its oncology portfolio and earnings trajectory.

BeOne's strong revenue growth (41% YoY in Q2; updated full-year guidance of $5 to $5.3b) is underpinned by rapid demand expansion for differentiated, best-in-class oncology therapies like BRUKINSA supported by a growing, aging population and increased global healthcare spending, both of which point to a sustainably expanding addressable market and future revenue growth.

See why 20 investors see BeOne Medicines as 19% undervalued.

Result: Fair Value of $433.02 (UNDERVALUED)

Still, the bullish BeOne Medicines story could unravel if competition squeezes BRUKINSA pricing, or if key late stage trials disappoint and reset earnings expectations.

Find out about the key risks to this BeOne Medicines narrative.

Another View on BeOne Medicines Valuation

There is a catch. On a simple P/E yardstick, BeOne Medicines trades at 60.8x, which is very high next to the US Biotechs group at 17.5x and peers at 27.9x. The fair ratio is 33.1x, so if prices drift toward that level, upside from here could be far tighter than the bullish narrative suggests.

For a closer look at how that earnings multiple stacks up and where it might settle over time, take a moment to See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed messages around BeOne Medicines can feel confusing, so move quickly, review the full picture carefully, and weigh its 4 key rewards and 1 important warning sign.

Looking for more BeOne Medicines style investment ideas?

If BeOne Medicines has sharpened your appetite for focused research, do not stop here. Use the tools available and keep building a watchlist that truly fits your goals.

• Zero in on quality at a discount and check out the 33 high quality undervalued stocks that currently line up with strong fundamentals and sensible balance sheets.
• Prioritize resilience and capital preservation by scanning the 30 resilient stocks with low risk scores that score well on financial strength and earnings stability.
• Spot future candidates before the crowd moves and review the 16 high quality undiscovered gems quietly combining robust metrics with under-the-radar market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com